179 related articles for article (PubMed ID: 31126990)
1. High ORRs Seen with Tagraxofusp-erzs in BPDCN.
Cancer Discov; 2019 Jul; 9(7):OF1. PubMed ID: 31126990
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jen EY; Gao X; Li L; Zhuang L; Simpson NE; Aryal B; Wang R; Przepiorka D; Shen YL; Leong R; Liu C; Sheth CM; Bowen S; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
Clin Cancer Res; 2020 Feb; 26(3):532-536. PubMed ID: 31548341
[TBL] [Abstract][Full Text] [Related]
3. Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.
Pemmaraju N; Konopleva M
Blood Adv; 2020 Aug; 4(16):4020-4027. PubMed ID: 32841341
[TBL] [Abstract][Full Text] [Related]
4. Treatment of leptomeningeal disease in blastic plasmacytoid dendritic cell neoplasm following tagraxofusp-erzs induction.
Vangala DB; Nilius-Eliliwi V; Mika T; Gambichler T; Stranzenbach R; Schroers R
Haematologica; 2022 Aug; 107(8):2004-2007. PubMed ID: 35385925
[No Abstract] [Full Text] [Related]
5. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Alfayez M; Konopleva M; Pemmaraju N
Expert Opin Biol Ther; 2020 Feb; 20(2):115-123. PubMed ID: 31801379
[No Abstract] [Full Text] [Related]
6. Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Hammond D; Pemmaraju N
Hematol Oncol Clin North Am; 2020 Jun; 34(3):565-574. PubMed ID: 32336420
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Kharfan-Dabaja MA; Cherry M
Hematol Oncol Clin North Am; 2020 Jun; 34(3):621-629. PubMed ID: 32336425
[TBL] [Abstract][Full Text] [Related]
9. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
Luskin MR; Lane AA
Haematologica; 2024 Jan; 109(1):44-52. PubMed ID: 36951152
[TBL] [Abstract][Full Text] [Related]
10. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Lee SS; McCue D; Pemmaraju N
Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
[TBL] [Abstract][Full Text] [Related]
11. Tagraxofusp Treatment: Implications for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Morin A; Kechedjian F; Walton P; Tavakoli A
Clin J Oncol Nurs; 2021 Apr; 25(2):E10-E16. PubMed ID: 33739343
[TBL] [Abstract][Full Text] [Related]
12. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wilson NR; Pemmaraju N
Expert Opin Pharmacother; 2022 Mar; 23(4):431-438. PubMed ID: 35060807
[TBL] [Abstract][Full Text] [Related]
13. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
Egger A; Coello D; Kirsner RS; Brehm JE
J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
[TBL] [Abstract][Full Text] [Related]
14. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
Economides MP; McCue D; Lane AA; Pemmaraju N
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):941-946. PubMed ID: 31465247
[No Abstract] [Full Text] [Related]
15. Tagraxofusp in myeloid malignancies.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Neri A; Imovilli A; Morabito F; Vigna E; Gentile M
Hematol Oncol; 2024 Jan; 42(1):e3234. PubMed ID: 37846131
[TBL] [Abstract][Full Text] [Related]
16. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Pemmaraju N; Lane AA; Sweet KL; Stein AS; Vasu S; Blum W; Rizzieri DA; Wang ES; Duvic M; Sloan JM; Spence S; Shemesh S; Brooks CL; Balser J; Bergstein I; Lancet JE; Kantarjian HM; Konopleva M
N Engl J Med; 2019 Apr; 380(17):1628-1637. PubMed ID: 31018069
[TBL] [Abstract][Full Text] [Related]
17. Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
Tandon A; Zhang Y; Sokol L
Drugs Today (Barc); 2019 Dec; 55(12):735-742. PubMed ID: 31942876
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N; Sweet KL; Stein AS; Wang ES; Rizzieri DA; Vasu S; Rosenblat TL; Brooks CL; Habboubi N; Mughal TI; Kantarjian H; Konopleva M; Lane AA
J Clin Oncol; 2022 Sep; 40(26):3032-3036. PubMed ID: 35820082
[No Abstract] [Full Text] [Related]
19. Tagraxofusp: First Global Approval.
Syed YY
Drugs; 2019 Apr; 79(5):579-583. PubMed ID: 30859413
[TBL] [Abstract][Full Text] [Related]
20. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.
Taylor J; Haddadin M; Upadhyay VA; Grussie E; Mehta-Shah N; Brunner AM; Louissaint A; Lovitch SB; Dogan A; Fathi AT; Stone RM; Tallman MS; Rampal RK; Neuberg DS; Stevenson KE; Horwitz SM; Lane AA
Blood; 2019 Aug; 134(8):678-687. PubMed ID: 31243042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
